Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799227 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00799227 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 56 participants.
The verdict
NCT00799227, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant in the study eye of vitrectomized subjects with diabetic macular edema. Subjects will be followed for 26 weeks.
Interventions
- DRUG Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2009-01-01 |
| Est. Completion | 2009-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00799227
The ClinicalTrials.gov registry entry for NCT00799227 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dexamethasone is the first listed.
NCT00799227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00799227 about?
NCT00799227 is a clinical study titled "Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema". The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant in the study eye of vitrectomized subjects with diabetic macular edema. Subjects will be followed for 26 weeks.
What is the current status of trial NCT00799227?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2009-01-01. Estimated completion is 2009-12-01.
What interventions are being tested in trial NCT00799227?
The interventions under investigation include: Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT00799227?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.